Hydrea Related Published Studies
Well-designed clinical trials related to Hydrea (Hydroxyurea)
Hydroxyurea and growth in young children with sickle cell disease. [2014]
Immunologic effects of hydroxyurea in sickle cell anemia. [2014]
Impact of hydroxyurea on clinical events in the BABY HUG trial. [2012]
Effect of hydroxyurea treatment on renal function parameters: results from the
multi-center placebo-controlled BABY HUG clinical trial for infants with sickle
cell anemia. [2012]
Genotoxicity associated with hydroxyurea exposure in infants with sickle cell
anemia: results from the BABY-HUG Phase III Clinical Trial. [2012]
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. [2011.12.01]
Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial. [2011.10.19]
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. [2011.05]
Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. [2010.12.14]
Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. [2010.12]
The impact of hydroxyurea on career and employment of patients with sickle cell anemia. [2010.11]
Hydroxyurea and Acute Painful Crises in Sickle Cell Anemia: Effects on Hospital Length of Stay and Opioid Utilization During Hospitalization, Outpatient Acute Care Contacts, and at Home. [2010.09.21]
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. [2010.06]
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. [2010.02]
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. [2010.02]
Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. [2010.01.01]
Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal
muscular atrophy. [2010]
The impact of hydroxyurea on career and employment of patients with sickle cell
anemia. [2010]
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of
study design. [2010]
Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. [2009.10]
The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. [2009.09.03]
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. [2009.08.06]
Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. [2008.12]
The effect of hydroxyurea in spinal muscular atrophy cells and patients. [2008.05.15]
Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. [2007.12]
Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. [2007.11]
Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. [2007.07.01]
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. [2007.03.15]
Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. [2007]
Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. [2006.12]
Hydroxyurea and sickle cell anemia: effect on quality of life. [2006.08.31]
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). [2006.06]
Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. [2005.07.22]
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. [2005.07.07]
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. [2005.04.08]
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. [2005.04]
Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression. [2004.08]
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. [2004.03.05]
A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). [2004.03]
Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival. [2004]
Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix. [2004]
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. [2003.08]
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. [2003.05]
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). [2003.05]
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. [2003.04.02]
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. [2002.12.06]
The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. [2002.07]
Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296. [2002.05]
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. [2002.04.01]
Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. [2001.12.01]
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. [2001.07.27]
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. [2000.09.29]
Combination therapy with hydroxyurea versus without hydroxyurea as first line treatment options for antiretroviral-naive patients. [2000.09]
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. [2000.09]
Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. [2000.05]
A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study. [2000.04]
Hydroxyurea for HIV infection. [1998.04]
[Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age] [1998.03]
Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. [1998]
Well-designed clinical trials possibly related to Hydrea (Hydroxyurea)
Front-line therapy in polycythemia vera and essential thrombocythemia. [2012]
Influence of severity of anemia on clinical findings in infants with sickle cell
anemia: analyses from the BABY HUG study. [2012]
Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. [2011.06]
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). [2011.05.14]
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. [2011.04.15]
The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. [2011.03]
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. [2011.02]
Randomized trial of zileuton for treatment of COPD exacerbations requiring
hospitalization. [2011]
The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results
of the multi-centre CHAMPS trial. [2011]
Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study. [2010.11]
Recruitment of infants with sickle cell anemia to a Phase III trial: Data from the BABY HUG study. [2010.08.24]
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. [2010.05]
Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. [2010.01]
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. [2009.06.20]
Hematopoietic stem cell transplantation for children with sickle cell disease. [2009.01.21]
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. [2008.12.01]
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. [2008.02.20]
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. [2008.02.01]
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. [2008.01.01]
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. [2007.08]
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. [2007.06]
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. [2007.05]
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. [2007]
Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: treatment with immunomodulator, more is not better. [2006.06]
Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects. [2006.02]
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. [2005.12.03]
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. [2005.08]
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. [2005.06]
[Comparison of therapeutic effects of low-dose versus high-dose interferon alpha-2b treatment on chronic myelocytic leukemia: a prospective randomized study] [2005.05.25]
The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude. [2005.02]
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. [2004.07.15]
Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. [2004.06.15]
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. [2004.06.01]
Sickle cell disease: primary stroke prevention. [2004.06]
Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. [2004.03]
Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. [2004.02]
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. [2003.12]
A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses. [2003.12]
Combined-modality therapy of locally advanced cervical cancer. [2003.05.15]
Divergent nitric oxide bioavailability in men and women with sickle cell disease. [2003.01.21]
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. [2003.01.03]
What is the standard treatment in essential thrombocythemia. [2002.08]
|